- Home
- JDZG vs IGC Comparison
JDZG vs IGC Comparison
Compare JDZG & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JDZG
- IGC
- Stock Information
- Founded
- JDZG 2020
- IGC 2005
- Country
- JDZG China
- IGC United States
- Employees
- JDZG N/A
- IGC N/A
- Industry
- JDZG Other Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- JDZG Real Estate
- IGC Health Care
- Exchange
- JDZG Nasdaq
- IGC Nasdaq
- Market Cap
- JDZG 29.3M
- IGC 26.9M
- IPO Year
- JDZG 2024
- IGC N/A
- Fundamental
- Price
- JDZG $0.72
- IGC $0.37
- Analyst Decision
- JDZG
- IGC Strong Buy
- Analyst Count
- JDZG 0
- IGC 2
- Target Price
- JDZG N/A
- IGC $3.63
- AVG Volume (30 Days)
- JDZG 201.2K
- IGC 258.8K
- Earning Date
- JDZG 12-03-2024
- IGC 11-12-2024
- Dividend Yield
- JDZG N/A
- IGC N/A
- EPS Growth
- JDZG N/A
- IGC N/A
- EPS
- JDZG 0.06
- IGC N/A
- Revenue
- JDZG $2,195,958.00
- IGC $1,183,000.00
- Revenue This Year
- JDZG N/A
- IGC N/A
- Revenue Next Year
- JDZG N/A
- IGC $13.57
- P/E Ratio
- JDZG $11.31
- IGC N/A
- Revenue Growth
- JDZG 52.08
- IGC N/A
- 52 Week Low
- JDZG $0.45
- IGC $0.25
- 52 Week High
- JDZG $15.08
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- JDZG N/A
- IGC 49.63
- Support Level
- JDZG N/A
- IGC $0.33
- Resistance Level
- JDZG N/A
- IGC $0.42
- Average True Range (ATR)
- JDZG 0.00
- IGC 0.03
- MACD
- JDZG 0.00
- IGC 0.00
- Stochastic Oscillator
- JDZG 0.00
- IGC 51.89
About JDZG JIADE LIMITED Common stock
Jiade Ltd Ltd is engaged in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platforms and auxiliary solutions. The Group offers pre-enrollment guidance on school/selection and application development, training for entrance exams, and assistance in the application process. The Group also offers offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance in the People's Republic of China.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.